OMER Omeros Corp.

19.43-0.69 (-3.43%)
Close: August 23, 2019

Quote

Previous Close
$19.43
Day Range
$19.33-$20.08
52 Week Range
$10.30-$27.00
Volume
464,627
Avg Volume
493,615
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$957.67M
Enterprise Value (EV)
$1.08B
PE Ratio
-
EV/EBITDA
-9.73
Price/Sales
33.20
Price/Book
-
PEG Ratio
0.16

Financials

Revenue
$29.87M
Gross Profit
$28.88M
EBITDA
-$111.26M
EPS, ttm
-$2.08
Profit Margin
-
Revenue/Employee
$126.56K
Next Earnings Date
11/11/2019 (78 days)
Debt to Equity
-151%
Debt
$185.46M
Cash
$60.50M
Net Debt
$124.96M

Performance

Beta
1.39
200 Day Moving Avg
$15.72
50 Day Moving Avg
$16.40
52 Week Change
-12.16%
YTD Change
60.54%
1 Month Change
27.66%
3 Month Change
8.79%
6 Month Change
39.58%
1 Year Change
-12.16%
2 Year Change
27.03%
5 Year Change
50.54%

Share Count

Shares Outstanding
49.3M
Float
46.3M
Restricted Shares
3.0M
Restricted Shares, %
6.01%

Omeros Corp. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Gregory A. Demopulos

Website: http://www.omeros.com

Description: Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Employees: 236